Evidence map›Paper›PMID 40479056›Full record

ArticleScience advances2025

Enhancer RNA-mediated transcriptional regulatory programs reveal the malignant progression of glioma.

Yingying Ma, Shuyuan Wang, Yijie Jia, Shijie Wang, Wendian Liu, Jiaxin Yu, Jun Wang, Jingkai Geng, Jiayi Zhao, Zheng Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Metamorphosis and lncRNAs: A Close Relationship.Genesis (New York, N.Y. : 2000) · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yingying MaCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0000-0002-6245-2200
Shuyuan WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0000-0001-9571-0299
Yijie JiaCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0009-0003-1115-7038
Shijie WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.
Wendian LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0009-0004-5181-698X
Jiaxin YuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0000-0003-0665-6636
Jun WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.
Jingkai GengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0009-0003-3211-9591
Jiayi ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0009-0006-8675-5552
Zheng ZhaoBeijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.ORCID 0000-0001-8945-9632
Juan XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0000-0002-3709-4165
Hui LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China.ORCID 0000-0001-9549-2615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To systematically investigate the molecular and pathological mechanisms of enhancer RNA (eRNA)-mediated transcriptional regulation in glioma recurrence and progression, transcriptomic, regulatome, and genomic data were integrated to analyze eRNA behavior in lower-grade gliomas (stages II/III) and glioblastomas (stage IV). Most eRNAs exhibited dynamic expression during glioma progression, regulated by master transcription factors (TFs) and affected by genomic mutations. The constructed perturbed TF-mediated eRNA-promoter regulatory landscape revealed that rewiring eRNA-promoter networks contributed to glioma malignancy. Drug response-related eRNAs associated with poor prognosis were identified, highlighting their clinical potential. Overall, integrative analysis highlights the critical role of eRNA-mediated regulatory rewiring in glioma progression, providing valuable insights into transcriptional mechanisms and potential therapeutic targets.

Indexed as

Enhancer RNAsGliomaCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMutationPromoter Regions, GeneticTranscription FactorsEnhancer RNAsTranscription Factors

Identifiers

PMID40479056
PMCPMC12143383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.